In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18F-AV-133 Academic Article uri icon


  • UNLABELLED: PET provides a noninvasive means to evaluate the functional integrity of the presynaptic monoaminergic system in the living human brain. METHODS: In this study, a novel (18)F-labeled tetrabenazine derivative, (18)F-(+)fluoropropyldihydrotetrabenazine ((18)F-AV-133), was used for the noninvasive assessment of the vesicular monoamine transporters type 2 (VMAT2) in 17 Parkinson disease (PD) patients and 6 healthy controls. The binding potential (BP) of (18)F-AV-133 was calculated using Logan graphical analysis. Voxel-based and volume-of-interest-based analyses of BP images were performed to examine brain regional reductions in VMAT2 density in PD. RESULTS: VMAT2 BP was decreased by 81% in the posterior putamen, 70% in the anterior putamen, and 48% in the caudate nucleus of PD patients. Voxel-based analysis demonstrated VMAT2 reductions in the striatum and mid brain of PD patients. Furthermore, VMAT2 BPs in the caudate nuclei significantly correlated with the clinical severity of PD. CONCLUSION: These findings indicate that the novel (18)F-labeled ligand (18)F-AV-133 can sensitively detect monoaminergic terminal reductions in PD patients. Studies with (18)F-AV-133 may allow the presymptomatic identification of individuals with disorders characterized by degeneration of dopaminergic nigrostriatal afferents.


  • Okamura, N
  • Villemagne, VL
  • Drago, J
  • Pejoska, S
  • Dhamija, RK
  • Mulligan, RS
  • Ellis, JR
  • Ackermann, U
  • O'Keefe, G
  • Jones, G
  • Kung, HF
  • Pontecorvo, MJ
  • Skovronsky, D
  • Rowe, CC

publication date

  • February 1, 2010

has subject area